News & Events

For Immediate Release

Bookmark & Share
Contact: John Sterling, 914-740-2196,
GEN Reports on Novel ADME/Tox Technologies

New Rochelle, NY, March 15, 2012—Too many new drug compounds fail in late-stage clinical trials due to inefficacy and safety concerns, reports Genetic Engineering & Biotechnology News (GEN). With the oft-cited cost of over $800 million to bring a new drug to market, a compelling need exists for improved early-stage drug screening, according to the March 15 issue of GEN.

“The importance of having developed a sound and scientifically based ADME/Tox strategy is one of the key requirements for any biopharmaceutical company intent on creating and marketing successful drug products,” said John Sterling, Editor in Chief of GEN. “Without such a plan in place all the drug discovery and R&D activities can wind up going for naught if the product does not make it through clinical trials because of toxicity and safety issues.”

A number of companies have developed innovative techniques to help biofirms address ADME/Tox questions. For example, Simulations Plus’ ADMET Predictor software mathematically correlates measured chemical-compound properties with their molecular descriptors to build predictive models. Currently, the application offers 133 predictive models and can process approximately 200,000 compounds per hour on a personal computer.

Assays using primary cells can provide more accurate predictions of in vivo compound activity. But it can be difficult to obtain a needed and requisite number of primary cells. Medicyte has a technology available called upcyte® that addresses this major concern in using primary cells for high-throughput-screening operations.

Also discussed in the GEN article are ADME/Tox solutions developed by ICDD-sas, APSciences , In Vitro ADMET Laboratories, and the University of Leipzig.


For a copy of the March 15 issue of GEN, please call (914) 740-2122, or email:

Genetic Engineering & Biotechnology News, which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.